Trial Profile
Phase III Confirmatory Study ; Comparison of efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2022
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary) ; Maxacalcitol
- Indications Secondary hyperparathyroidism
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Japan; AbbVie
- 19 Jun 2014 New trial record
- 24 Apr 2012
- 24 Feb 2012